Login / Signup

The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.

Francis A FarrayeTaha QaziPaulo Gustavo KotzeGregory T MooreRajiv MundayatNervin LawendyPuza P SharmaDonna T Judd
Published in: Alimentary pharmacology & therapeutics (2021)
Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI.
Keyphrases
  • ulcerative colitis
  • body mass index
  • weight gain
  • rheumatoid arthritis
  • physical activity
  • study protocol
  • randomized controlled trial